Molecular Partners announced Patrick Amstutz as CEO, detailing the career background of Martin Steegmaier, including his previous roles at Roche, MorphoSys, and Boehringer Ingelheim.
1 report, 1 independent
Updated Aug 21
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Molecular Partners announced Patrick Amstutz as CEO, detailing the career background of Martin Steegmaier, including his previous roles at Roche, MorphoSys, and Boehringer Ingelheim.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Molecular Partners
biopharmaceutical company based in Zürich, Switzerland
Nothing else this week.
-
Patrick Amstutz
Nothing else this week.
- Martin
Related events
Coverage
Newest first; wire copies grouped- GlobeNewswireMolecular Partners appoints Martin Steegmaier as Chief Scientific Officer to drive discovery of next-gen DARPin therapeutics Extensive experience from senior oncology research roles at Roche, MorphoS